OKYO Pharma Announced That Screening And Recruitment Of Patients Has Started For A Phase 2 Trial Of OK-101 Neuropathic Corneal Pain
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma has commenced patient screening and recruitment for a Phase 2 trial of OK-101 for neuropathic corneal pain. The trial will involve 48 patients and aims to measure pain relief using the Visual Analog Scale.
October 16, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OKYO Pharma has started a Phase 2 trial for its drug OK-101, targeting neuropathic corneal pain. The trial will assess pain relief in 48 patients over 12 weeks.
The initiation of a Phase 2 trial is a significant step in drug development, indicating progress in OKYO's pipeline. Successful results could lead to increased investor confidence and a potential stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100